(Q35194336)

English

Atazanavir

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

7 August 2017

1 reference

Europe PubMed Central

Atazanavir. (English)

1 reference

Europe PubMed Central

7 August 2017

1 reference

based on heuristic

inferred from title

Caroline M Perry

2

object named as

Caroline M Perry

1 reference

Europe PubMed Central

7 August 2017

author name string

David R Goldsmith

1

1 reference

Europe PubMed Central

7 August 2017

publication date

1 January 2003

1 reference

Europe PubMed Central

7 August 2017

1 reference

Europe PubMed Central

7 August 2017

63

1 reference

Europe PubMed Central

7 August 2017

16

1 reference

Europe PubMed Central

7 August 2017

1679-93; discussion 1694-5

1 reference

Europe PubMed Central

7 August 2017

https://scigraph.springernature.com/pub.10.2165/00003495-200363160-00003

0 references

BMS-232632 (Novartis/Bristol-Myers Squibb).

1 reference

https://pubmed.ncbi.nlm.nih.gov/12904086

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/12904086

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632

1 reference

https://pubmed.ncbi.nlm.nih.gov/12904086

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable

1 reference

https://pubmed.ncbi.nlm.nih.gov/12904086

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/12904086

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12904086

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/12904086

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/12904086

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/12904086

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Atazanavir: a novel HIV-1 protease inhibitor

1 reference

https://pubmed.ncbi.nlm.nih.gov/12904086

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00003495-200363160-00003

1 reference

Europe PubMed Central

7 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

7 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35194336&oldid=1574378516"